Studying Roxadustats Impact on Bone Health, Mood, and Nerve-Muscle Function in Adults With Kidney Failure on Hemodialysis

What this Trial Is About

People with severe kidney failure who require regular hemodialysis often face several health challenges such as anemia, bone health problems, and mental health issues like depression and anxiety. This research aims to understand whether Roxadustat, a newer oral medicine for anemia, can also affect bone health and psychological well-being in these patients. The study focuses on assessing bone density, mood symptoms, and nerve and muscle changes in people undergoing hemodialysis. The trial randomly assigns 46 patients on chronic hemodialysis into two groups. One group receives Roxadustat pills three times a week alongside their usual care, while the other group continues with conventional anemia treatment including injectable medications. The treatment period lasts for 6 months, during which Roxadustat dosing may be adjusted based on hemoglobin levels. Participants will have regular evaluations including blood tests, bone density scans using quantitative computed tomography, nerve and muscle ultrasound exams, and questionnaires assessing depression and anxiety. These assessments occur at the start and at intervals during the 6-month study to measure changes in bone mineral density, mood, and neuromuscular structure. Researchers will compare results between the two groups to understand the broader effects of Roxadustat in hemodialysis patients.

Roxadustat for Bone and Neuropsychiatric Aspects in Hemodialysis Patients